Clinical utility of Opicapone in the management of Parkinson's Disease : a short review on emerging data and place in therapy by Azevedo Kauppila, Linda et al.
R E V I E W
Clinical Utility of Opicapone in the Management 
of Parkinson’s Disease: A Short Review on 
Emerging Data and Place in Therapy
Linda Azevedo Kauppila1 
Daniela Pimenta Silva1 
Joaquim J Ferreira2–4
1Department of Neurosciences and 
Mental Health, Centro Hospitalar 
Universitário Lisboa Norte, Lisbon, 
Portugal; 2CNS - Campus Neurológico, 
Torres Vedras, Portugal; 3Instituto de 
Medicina Molecular João Lobo Antunes, 
Lisbon, Portugal; 4Laboratory of Clinical 
Pharmacology and Therapeutics, 
Faculdade de Medicina da Universidade 
de Lisboa, Lisbon, Portugal 
Abstract: Parkinson’s disease (PD) is a prevalent neurodegenerative disorder, and levodopa 
(L-dopa) remains the most efficacious drug treatment for PD and a gold-standard for 
symptom control. Nonetheless, a significant majority of PD patients develop motor fluctua-
tions over their disease course, with a significant impact on quality-of-life, meaning control 
of such complications translates into a fundamental clinical need. Catechol-O-methyl trans-
ferase (COMT) inhibitors (COMT-i) are used as first-line adjuvant therapy to L-dopa for end- 
of-dose (EoD) motor fluctuations, since they increase L-dopa availability in the brain by 
inhibiting its peripheral metabolism. Opicapone (OPC), a once-daily, long-acting COMT-i, is 
the most recent and potent of its class, having been licensed in Europe in 2016 as an add-on 
to preparations of L-dopa/DOPA decarboxylase inhibitors in PD patients with EoD motor 
fluctuations. More recently, it has also received approval in the USA and Japan in 2020. Two 
high-quality positive efficacy studies (double-blind Phase III clinical trials) established OPC 
efficacy with significant reduction in OFF time (average 60 minutes vs placebo), without 
concomitant increase of distressing dyskinesias during ON time. These beneficial effects 
were sustained in open-label extension studies, without unexpected safety issues or adverse 
events, with dyskinesia having been the most frequent complaint. OPC also avoids liver 
toxicity and gastrointestinal issues compared with previous COMT-i. In this review, we 
aimed to cover OPC’s lifecycle (synthesis to commercialization), its clinical pharmacological 
data, safety, tolerability and pharmacovigilance evidence, and discuss its role in the manage-
ment of motor fluctuations in PD as well as its emerging place in international 
recommendations. 
Keywords: Parkinson’s disease, opicapone, motor fluctuations, COMT inhibitor, safety, 
tolerability
Introduction
Parkinson’s disease is the second most common neurodegenerative disease 
worldwide.1 Although no available therapies alter the underlying neurodegenerative 
process, symptomatic therapies can improve patient quality-of-life. Levodopa 
(L-Dopa) continues to be the most effective treatment for motor symptoms of 
PD.2 With sustained treatment with L-Dopa high doses and longer disease duration, 
motor complications emerge with a significant impact on patient’s quality-of-life.3–6
Catechol-O-methyl transferase (COMT) inhibitors are currently used as add-on 
therapy to L-Dopa for the treatment of end-of-dose motor fluctuations, as they 
inhibit peripheral L-Dopa metabolism and increase its delivery to the brain.7 
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A hydrophilic 1,2,4-oxadiazole analog with a pyridine 
N-oxide residue at position 3 was developed to provide 
high COMT inhibitory potency and to avoid cell toxicity 
risk,8 giving rise to the development of opicapone (OPC), 
a third generation COMT inhibitor.
Here we aim to overview OPC’s lifecycle, since its 
conception to commercialization, the evidence about its 
efficacy, tolerability and safety profile, and to discuss its 
role in the management of motor fluctuations in PD in 
current clinical practice.
Opicapone Lifecycle: From 
Conception to Commercialization
Opicapone (OPC) is a hydrophilic 1,2,4-oxadiazole analog 
with the chemical name 2,5-dichloro-3-(5-[3,4-dihydroxy- 
5-nitrophenyl]-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 
1-oxide, also known as BIA 9–1067.8
Developmental Phase
OPC was developed to improve the limitations from other 
catechol-O-methyltransferase inhibitors (COMT-i), 
namely to reduce the risk of toxicity, improve peripheral 
tissue selectivity, and provide a more convenient dosage 
regimen.8
In vitro COMT inhibition by OPC was evaluated in rat 
liver and brain homogenates and compared to TLC. OPC 
achieved significant and maintained peripheral COMT 
inhibition up to 24 hours, with no measurable effect on 
central COMT.8 The concentration-dependent peripheral 
inhibitory potency was then evaluated in rats by giving 
increasing doses (0.03–3 mg/kg). OPC was found to be 
more potent than TLC, with an ED50 of 1.05±0.04 mg/ 
kg.8 The pharmacodynamic interaction with L-dopa was 
also compared, and OPC conferred a more conservative 
but sustained increase in L-dopa levels,8 virtually over the 
entire 24 hour period, thanks to a slow complex dissocia-
tion rate and a high binding affinity (sub-picomolar Kd).9
Preclinical Studies
In vitro and ex vivo Studies
In liver homogenates from rats administered with OPC, 
Tolcapone (TLC) and Entacapone (ENT), OPC demon-
strated a stronger and more sustained COMT inhibitory 
effect.10 One hour after administration, COMT inhibition 
was 99% with OPC vs 82% and 68% with TLC and ENT, 
respectively, at the same dose levels. Nine hours after 
administration, there was no COMT inhibition with ENT, 
TLC produced only a minimal inhibitory effect (16%), and 
OPC continued to inhibit COMT activity by 91%.10 
Equally the evaluation on brain catecholamines showed 
a significant increase of L-Dopa and dopamine, as OPC 
behaved as a tight-binding inhibitor of human recombinant 
S-COMT with an inhibitory 10-fold lower than the one 
obtained for TLC.10
Another study explored the pharmacological properties 
of OPC using rat (brain, kidney, liver, and erythrocytes) 
and human (hepatocytes) tissues. There was a very long 
and strong peripheral COMT activity inhibition (>80%), 
both of the hepatic and kidney enzymes.11 Upon oral 
administration of L-Dopa/benserazide, OPC led to 
a prolonged and sustained increase in the peripheral and 
central bioavailability of L-Dopa, from 2 hours up to 24 
hours, with concomitant reduction of 3-O-methyldopa 
(3-OMD) levels.11 The same study assessed the risk for 
cytotoxicity, OPC providing the lowest evidence for liver 
toxicity, and a larger safety margin when compared to 
TLC or ENT, as shown by the low potential in decreasing 
both the ATP content and mitochondrial membrane poten-
tial in human primary hepatocytes after a 24 hour incuba-
tion period.11
OPC was also studied in the Cynomolgus monkey with 
implanted microdialysis probes in the substantia nigra, 
dorsal striatum, and prefrontal cortex.12 There was 
a significant increase in brain and systemic bioavailability 
of levodopa and related metabolites: L-Dopa systemic 
exposure was increased by 2-fold, and the more pro-
nounced effects in the brain were observed in the prefron-
tal cortex with a 2.3-fold increase in the Area Under the 
Curve (AUC). The marked inhibitory effect of OPC upon 
peripheral COMT was also evidenced by a 5-fold reduc-
tion in plasma 3-OMD levels, and a 76–84% reduction in 
erythrocyte COMT activity.12
The results here described were in line with the data 
obtained in the initial development phase of the 
compound.8 On the basis of these promising results in 
animals, human pharmacology studies were conducted to 
evaluate the tolerability, pharmacokinetics and pharmaco-
dynamics of OPC in healthy subjects.
Phase I Clinical Trials
To date, as many as 33 phase I trials have been conducted 
on OPC use, with more than 1,000 subjects exposed.
In a human pharmacology study in young healthy male 
volunteers, OPC was well-tolerated and presented dose- 
proportional kinetics, following single oral doses (10– 
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1,200 mg).13 Despite the low plasma exposure (terminal 
elimination half-life of 0.8–3.2 hours), the levels of ery-
throcyte COMT inhibition were sustained far beyond the 
observable point of plasma drug clearance (observed half- 
life in human erythrocytes was 61.6 hours), independent of 
dose administration.13 This is probably due to the long 
residence time of the reversible complex formed between 
COMT and OPC, as shown by the slow dissociation pro-
cess (Koff = 1.9×10−6 s−1).9
Following an 8-day once-daily multiple-dose regimen 
up to 30 mg OPC, sulfation appears to be the main meta-
bolic pathway for OPC in humans, and bile is likely the 
main route of excretion.14,15 The systemic exposure 
increased in an approximately dose-proportional manner, 
with an apparent terminal half-life of 1.0–1.4 hours, max-
imum S-COMT inhibition (Emax) between 69.9% and 
98.0% following the last dose of OPC, and a half-life in 
excess of 100 hours, which was dose-independent.14 These 
results replicated the notion of a putative underlying rate 
constant comparable to the estimated dissociation rate 
constant of the COMT-OPC complex.9,13,14
Comparing the S-COMT inhibitory effect described in 
these studies, OPC was much stronger than what is 
reported for TLC and ENT in healthy subjects: Emax 
was 72% and 80% for TLC 100 mg and 200 mg,16 respec-
tively; 65% for ENT 200 mg;17 and S-COMT activity 
returned to baseline approximately 18 hours after TLC16 
and 8 hours after ENT.17 Remarkably, 24 hours after the 
last dose of OPC, S-COMT activity was still decreasing 
about 42.8%, 52.4%, 56.8%, and 64.9% in the 5 mg, 
10 mg, 20 mg, and 30 mg OPC groups, respectively.14
Regarding the effect on the L-Dopa pharmacokinetics 
profile throughout a day, repeated doses of OPC or con-
comitant administration with ENT were compared in 
healthy subjects. OPC was found to significantly increase 
the L-Dopa minimum plasma concentration (Cmin) and its 
systemic extent of exposure (AUC0–24).18 The reduced 
clearance and prolonged half-life of L-Dopa, with any 
OPC dose, resulted in a dose-dependent increase of 
L-Dopa Cmin of at least 2.5-fold.18 In addition, OPC may 
enhance stable L-Dopa plasma concentrations as it 
increases Cmin with no impact on L-Dopa fluctuation (as 
assessed by Cmax-Cmin).18 When compared to ENT, OPC 
provided a superior response upon the bioavailability of 
L-Dopa associated to more pronounced, long-lasting, and 
sustained COMT inhibition.18
A food-effect study was conducted to investigate the 
effect of food on the oral bioavailability of OPC.13 The 
authors concluded that the rate and extent of systemic 
exposure to OPC significantly decreased following conco-
mitant ingestion of a high-fat high-calorie meal. This was 
replicated in a further study in healthy subjects,19 however 
OPC COMT inhibition was not affected by concomitant 
administration of a moderate meal.19
The effect of moderate liver impairment on pharmaco-
kinetics and pharmacodynamics of OPC was assessed in 
an open-label, parallel-group trial with individuals with 
moderate hepatic dysfunction (Child–Pugh category B, 
score to 7–9) and matched with healthy individuals.20 
The bioavailability of a single dose of OPC 50 mg was 
significantly higher in patients with moderate chronic 
hepatic impairment.20 The authors hypothesized that 
a reduced first-pass effect would be the reason for the 
increased exposure to OPC (AUC and Cmax), however no 
dose adjustment was needed in mild-to-moderate hepatic 
impairment due to its systemic elimination before the 
subsequent dose administration.20 Notably, there were no 
liver enzyme increments in any individual, none of them 
showed evidence of hepatic disease worsening, and the 
other phase I trials showed no changes in liver function 
monitoring.21
The effect of OPC on cardiac repolarization was also 
evaluated in 64 healthy subjects.22 There was no clinically 
relevant effect of OPC 50 and 800 mg vs placebo on 
cardiac depolarization or repolarization, and therapeutic 
(50 mg) as well as supratherapeutic (800 mg) had no QT- 
prolonging effect,22 further supporting its cardiac safety.
Reported drug-related adverse events (AEs) were mild 
in severity and clinical safety tests did not raise any safety 
concerns.13,14,18,21 The most common AEs were somno-
lence, headache, and gastrointestinal complaints, including 
nausea, vomiting, and diarrhea.21
Overall, these studies clearly suggest that OPC has 
a favorable safety, pharmacokinetic and pharmacodynamic 
profile, adequate for a once-daily regimen, which in the 
treatment of PD patients represent an advantage over ENT 
and TLC, prompting further studies in PD patients.
Phase II Clinical Trials
Two phase II clinical trials explored the effect of single 
and repeat-dose OPC on L-Dopa pharmacokinetics in 
Parkinson’s disease (PD) patients with end-of-dose motor 
fluctuations.23,24
These two multicenter, double-blind randomized con-
trolled trials were the first to study the effects of once daily 
doses of OPC on L-Dopa pharmacokinetics in PD 
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patients.23,24 OPC was found to significantly increase the 
extent of L-Dopa systemic exposure (as assessed by AUC) 
under both 15 and 30 mg OPC doses.23 Furthermore, peak 
L-Dopa exposure (as assessed by Cmax) was significantly 
increased under 30 mg OPC.23 Maximum COMT inhibi-
tion (Emax) ranged from 52% (5 mg OPC) to 80% (30 mg 
OPC)23 and 100% (100 mg OPC).24 Maximum decrease in 
the plasma 3-OMD was observed following administration 
of 100 mg OPC.24
Although the study was not designed for motor out-
comes, it found a dose-dependent and statistically signifi-
cant decrease in absolute OFF time and increase in ON 
time without dyskinesias compared with placebo.23,24 OPC 
was well tolerated when administered with standard 
release 100/25 mg L-Dopa/carbidopa or L-Dopa/ 
benserazide.23,24
Phase III Clinical Trials: BIPARK-I and 
BIPARK-II
The efficacy of oral once-daily OPC as an adjunctive 
therapy to L-Dopa in patients with PD and EoD motor 
fluctuations was evaluated in double-blind, multinational, 
Phase 3 trials (BIPARK I and BIPARK II; total treatment 
duration 14–15 weeks).25,26 BIPARK I also evaluated the 
noninferiority of OPC to ENT.21,25,27 In BIPARK I and 
BIPARK II, adjunctive OPC 50 mg/day provided better 
efficacy than add-on placebo in terms of improving motor 
fluctuations, with OPC significantly reducing time in the 
off state and increasing time in the on state.21,25–27
BIPARK I, which enrolled 600 PD patients with motor 
fluctuations, showed that OPC 50 mg was more efficacious 
than placebo in reducing OFF time and non-inferior to 
ENT.25 The mean reduction in the time spent in the OFF 
state in a day was 116.8 minutes for OPC 50 mg, 96.3 
minutes for ENT, and 56.0 minutes for placebo.25 This 
corresponds to a reduction in time in the OFF state of 60.8 
minutes daily versus placebo.25 Compared to ENT, OPC 
50 mg showed a tendency for a greater magnitude of effect 
in OFF-time reduction and performed better for both 
CGI-C and the PGI-C, suggesting a greater clinical 
benefit.25 Treatment-emergent AE (TEAE) were reported 
in 62 (54%) of 115 in the OPC 50 mg group; the most 
common ones were dyskinesia (five patients in the placebo 
group, 10 in the ENT group, 17 in the OPC 5 mg group, 
nine in the OPC 25 mg group, 18 in the OPC 50 mg 
group), insomnia (in 1, 7, 2, 7, and 7 patients, respec-
tively), and constipation (in 3, 5, 4, 0, and 7 patients, 
respectively).25 Serious AE were reported in six patients 
in the placebo group, eight in the ENT group, four each in 
the OPC 5 mg and 50 mg groups, and one in the OPC 
25 mg group.25 In BIPARK II, a total of 427 patients were 
randomized to 25 or 50 mg of OPC or placebo.26 In this 
study, OPC 25 and 50 mg were also more efficacious than 
placebo in reducing OFF state time (1.7, 2.0, and 1.1 
hours, respectively),21,26 with the adjusted treatment dif-
ference vs placebo being significant for the 50 mg OPC 
group (treatment effect, −54.3 minutes; p=0.008), but not 
for the 25 mg OPC group (treatment effect, −37.2 minutes; 
p=0.11).26 The most frequent AE in OPC (25 and 50 mg) 
vs placebo groups were dyskinesia (30, 36, and 11 
patients, respectively), constipation (12, 10, and 2 
patients), and dry mouth (13, 6, and 1 patient), as had 
already been identified in BIPARK.25,26
In summary, in two phase III clinical trials, OPC 50 mg 
demonstrated to be superior to placebo in OFF-time reduc-
tion without increasing ON time with troublesome dyski-
nesias in PD patients with EoD motor fluctuations. This 
benefit was maintained during 1-year follow-up with no 
major issues on its safety profile, even among older PD 
patients.25,26,28
No study has specifically assessed OPC effects on non- 
motor symptoms, but results from BIPARK I and BIPARK 
II studies showed a non-significant improvement in NMSS 
total score, which was more evident with OPC 50 mg, and 
numerical differences favoring OPC for both sleep and 
fatigue domains.25,26
BIPARK-I and BIPARK-II Extension Studies
In the 1-year, open-label (OL) extension studies of 
BIPARK I (n=495)29,30 and BIPARK II (n=286),26 OPC 
and L-Dopa dosages were adjusted based on clinical 
responses and/or associated AE. In patients receiving 
adjunctive OPC during the double-blind and extension 
phases (ie, OPC–OPC group), the beneficial effects of 
OPC on motor fluctuations that were observed in the 
double-blind phases were maintained during the 1-year 
extension phases of BIPARK I and BIPARK II.26,29,30 
Patients who switched from adjunctive placebo or ENT 
to adjunctive OPC at the end of the double-blind phase 
experienced significant (p<0.05) improvements in motor 
fluctuations during the 1-year BIPARK I extension 
phase.29 Add-on OPC treatment was associated with main-
tained improvements from baseline in UPDRS activities of 
daily living (Part II) and motor (Part III) scores during the 
open-label extension of BIPARK I, with mean UPDRS II 
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ON and OFF (OFF score; p=0.0043 vs prior placebo) and 
UPDRS III (p=0.0456 vs prior placebo) scores improving 
from baseline by −2.2, −4.4, and −7.4 points, 
respectively.27,30
Considering the BIPARK II OL phase, off-time reduc-
tion was maintained throughout this period, with −126.3 
minutes at 1-year open-label end point; the adjusted mean 
change from beginning to finish of the OL phase in off- 
time was −18.31 (95% CI=−43.56–6.95) minutes.26 Mean 
(SD) total on-time also increased by 24.9 (156.4) minutes, 
without or with unbothersome dyskinesia.26 During the 
OL phase, mean (SD) on-time associated with distressing 
dyskinesia increased by only 6.0 (129.1) minutes.26 With 
the conclusion of the 1-year BIPARK II extension phase, 
no worsening of non-motor symptoms during adjunctive 
OPC treatment was identified, with a mean improvement 
in NMSS total score of −4.2.31
Data from the BIPARK I and II double-blind and OL 
studies were combined in a more recent study in 2019.32 
Double-blind OPC treatment significantly reduced OFF 
time from a starting point of 6.1–6.6 OFF hours. The 
mean (95% CI) treatment effect vs placebo was −35.1 
minutes (p=0.0106) and −58.1 minutes (p<0.0001) for 
the 25 and 50 mg doses, respectively.32 OFF time reduc-
tions were accompanied by noteworthy increases in ON 
time without distressing dyskinesia (p<0.05 and p<0.0001 
for the 25 and 50 mg doses, correspondingly), and no 
significant differences were noted for ON time with both-
ersome dyskinesia.32 During the OL phase, patients pre-
viously treated with OPC 50 mg maintained a positive 
effect of this treatment in their patient diary registries, 
while patients treated with 25 mg further improved with 
OPC dose optimization, and switch from placebo to OPC 
resulted in important OFF time reductions and increased 
ON time.32 Therefore, over the course of 1 year of OL 
treatment, OPC steadily reduced OFF time and increased 
ON time without it translating into an increase of distres-
sing dyskinesia occurrence.32
Safety and Tolerability Data from Phase III Clinical 
Trials
OPC is generally well tolerated, with no clinically relevant 
effects on hepatobiliary function and no serious cases of 
hepatotoxicity having been previously reported in clinical 
trials.27 In a pooled and integrated safety analysis of 
BIPARK I and II and its extension studies, the most 
common TEAEs in OPC recipients (25 or 50 mg/day) 
were dyskinesia, constipation, insomnia, and dry mouth, 
most of which were of mild-to-moderate intensity and had 
no dose relationship.27,32
In both BIPARK I and II studies, the most common 
TEAE was dyskinesia, but it showed a tendency to 
decrease with time after visit four in all OPC groups (5, 
25, and 50 mg).21
In the OL 1-year extension phase of BIPARK II, the 
most common TEAEs were dyskinesia (21.5%), worsen-
ing PD (17.0%), falls (9.1%), CK increase (7.4%), insom-
nia (5.7%), and orthostatic hypotension (5.4%). Thirty-two 
(9.1%) patients withdrew the study due to AE. The most 
frequent TEAEs leading to study withdraw were dopami-
nergic effects: three patients (0.8%) for dyskinesia, three 
(0.8%) for hallucinations, one (0.3%) for orthostatic hypo-
tension, and one (0.3%) for worsening of PD. Most of 
these were mild-to-moderate, with the incidence of severe 
TEAE having been 11.3% (n=40).33 A total of five deaths 
occurred, which were considered to be unrelated to the 
treatment drug, specified below.21,26,33
Less than 1% of OPC receivers developed impulse 
control disorder (ICD) AE, and OPC treatment did not 
appear to increase the risk of ICDs or suicidality with 
longer-term treatment.27 No unanticipated safety concerns 
were recognized during the 1-year extension studies.27 
Continued use of OPC once-daily during 1-year (25 mg 
or 50 mg) was globally harmless and well tolerated, rein-
forcing its clinical utility in the management of PD motor 
fluctuations.34
In a subgroup analysis of pooled safety data in older 
PD patients (> 70 years old, 29% of the 766 BIPARK 
patients), OPC also seemed to be safe and well-tolerated, 
with most frequent TEAEs compared to younger patients 
having been hallucinations, visual hallucinations and 
weight decrease (adjusted to placebo).28 The OPC group 
had a higher discontinuation rate due to TEAEs and the 
most common were dyskinesia (2.6%) and vomiting 
(2.6%).28
BIPARK studies’ data were also pooled in order to 
better understand OPC’s role on hepatobiliary function.35 
No significant hepatic blood work changes from baseline 
to endpoint were detected in any treatment group.35 The 
occurrence of possibly clinically meaningful values was 
low and similar for placebo and OPC groups,35 with hepa-
tic-related AE having been lower in OPC groups (1.2%) vs 
placebo (3.1%).21 Notably, none of the hepatic events in 
the OPC groups led to the drug discontinuation.21
Another pooled analysis from BIPARK studies was 
conducted to assess potential OPC cardiac safety through 
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ECG parameters. No significant differences among groups 
were determined from baseline concerning QTcF/QTcB, 
PR, and heart rate (HR). The placebo-adjusted changes in 
QT/QTc were <1 ms for both OPC doses, and all upper 
limits of the two-sided 90% CI were significantly below 
the threshold of 10 ms. ECG morphological abnormalities 
were observed in rare subjects and in comparable propor-
tions across groups. Moreover, neither arrhythmias nor 
myocardial ischemia were verified. To conclude, OPC 
presented no clinically noteworthy effects on cardiac con-
duction and repolarization as assessed by changes in QT/ 
QTc, maximum QRS duration, PR intervals, and HR.21
No deaths occurred during BIPARK I; one death from 
pneumonia was registered in the placebo group during the 
double-blind phase of BIPARK II.21 In the OL phase of 
BIPARK II, deaths were reported due to septic shock, 
traumatic brain injury, cerebral hemorrhage, small cell 
lung cancer, and an unknown cause, but none were 
deemed to be associated to treatment.21,26
Commercialization
On the basis of the clinical development program compris-
ing 27 Phase I studies, two Phase II studies and two Phase 
III studies, on April 2016, the European Medicines 
Agency adopted a positive opinion recommending grant-
ing for marketing authorization of Ongentys®.36 In 
June 2016, the European Commission authorized OPC as 
an adjunct therapy to levodopa/DOPA decarboxylase inhi-
bitors (DDCIs) in adult patients with PD and EoD motor 
fluctuations.
In Europe, OPC is currently marketed in Germany, the 
United Kingdom, Spain, Portugal, and Italy. On 
April 2020, OPC was approved by the US Food and 
Drug Administration.37
In Japan, OPC received manufacturing and marketing 
approval on June 2020.38 The formulation developed by 
ONO Pharmaceutical Co. Ltd. (Osaka, Japan) is a tablet 
formulation, as opposed to the capsule used in clinical 
trials BIPARK I and II and marketed in approved coun-
tries. A phase I open-label, randomized, 2-way, 2-period 
crossover clinical trial compared the pharmacokinetic 
characteristics of both formulations of OPC, after single 
oral administration to healthy Japanese volunteers.39 
Compared with similar capsule doses (25 and 50mg), the 
proposed smaller tablet formulation was associated with 
higher Cmax and AUClast/0-∞ values, but similar t1/2 and 
tmax values.39 OPC tablets were further studied in Japanese 
PD patients with motor fluctuations in a randomized 
placebo-controlled study, the double-blind part of 
COMFORT-PD (COMt-inhibitor Findings from 
Opicapone Repeated Treatment for Parkinson’s 
Disease).40 The study design was similar to BIPARK 
I and II clinical trials. Recruited Japanese PD patients 
had lower OFF-time and used lower L-Dopa doses.40 
The main conclusion of this study is that once-daily 
adjunct OPC tablets at doses of 25 and 50 mg significantly 
reduced OFF-time compared with placebo among 
Japanese L-Dopa treated patients with PD and motor fluc-
tuations, with no dose dependency between OPC tablet 
dosages.40 Overall, the efficacy results in this study are 
broadly consistent with those seen in BIPARK I and II, 
however the least squares mean changes in OFF-time were 
numerically lower in Japanese patients than in the 
BIPARK I and II studies for OPC 25 mg, 50 mg, and 
placebo.26,40
Post Hoc Analysis from Clinical 
Trials
Recent Fluctuators
PD patients enrolled in BIPARK-I and II were divided in 
subgroups according to disease- and therapy-related 
characteristics,41 to evaluate the added benefit of OPC 
50 mg across the motor fluctuations spectrum of PD. 
Five hundred and twenty-two patients were randomized 
to placebo (PLC) (n=257) and OPC 50 mg (n=265). OPC 
50 mg was superior to PLC in all subgroups, except the 
one treated with 700 mg/day L-Dopa or more (p=0.064). 
OPC 50 mg was more efficacious in patients who have 
lower disease duration (less than 8 years of duration), 
lower Hoehn and Yahr (HY) (less than 2.5), lower duration 
of motor fluctuations (onset in 1 year or less), and lower 
L-Dopa intakes (less than 4) and daily amount (less than 
700 mg).41 Furthermore, there was a trend towards a lower 
incidence of dopaminergic-related TEAEs in the same 
subgroups of patients.41
COMTi-naïve patients from BIPARK-I who were 
‘recent fluctuators’ (ie, patients having an onset of motor 
fluctuations in 1 year or less of study baseline) were 
further included in a post-hoc analysis.42 The least- 
squares (LS) mean (standard error – SE) reduction from 
baseline in absolute OFF-time was 124 minutes (21.0) for 
the OPC group compared to 84.1 (21.4) and 56.7 (21.8) 
minutes for ENT and PLC groups, respectively.42 The LS 
mean (SE) increase in absolute ON-time from baseline 
was 131.2 minutes (21.1) for the OPC group, as opposed 
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to both ENT and PLC groups [85.5 (21.4) and 32.7 (21.9) 
minutes, respectively].42 Overall OPC 50 mg demon-
strated added benefit as a first adjunctive COMTi, in 
comparison with PLC and ENT, in “recent fluctuators”.
A more conservative analysis including 97 COMT- 
naïve “recent fluctuator” patients further demonstrated 
that OPC 50 mg numerically decreased the absolute OFF- 
time and significantly increased absolute ON-time (by 
approximately 1 hour), compared with ENT, when used 
as first adjunctive COMTi in patients recently diagnosed 
with motor fluctuations.43
Levodopa Monotherapy
A Full Analysis Set from BIPARK-I and II combining 
PLC and OPC groups demonstrated an approximately 
2-fold greater improvement, compared to PLC, in the 
mean change from baseline in OFF-time when OPC 
50 mg was added to any of the levodopa-containing treat-
ment regimens, namely L-Dopa only, L-Dopa plus dopa-
mine agonists (DA) and L-Dopa plus monoamine oxidase 
B inhibitor (MAO-Bi).44 Interestingly, OFF-time reduction 
was greater when OPC 50 mg was used as first add-on to 
L-Dopa.44
Further exploratory post-hoc analysis in patients trea-
ted with L-Dopa in monotherapy was performed.45 The LS 
mean reduction from baseline in absolute OFF-time was 
109.2 minutes (95% CI, –147.9 to –70.4) for the OPC 
group compared to 40.3 minutes (95% CI, –80.7 to 0) 
for the PLC group.45 Similarly, the LS mean increase in 
absolute ON-time from baseline was 96.7 minutes (95% 
CI, 58.1 to 135.3) for the OPC group, while the PLC group 
experienced a gain of 16.9 minutes (95% CI, –23.3 to 
57.0).45 Thus, OPC 50 mg was efficacious in decreasing 
the absolute OFF-time [absolute difference = 68.8 minutes 
(95% CI, –124.8 to –12.8)] and increasing the absolute 
ON-time [absolute difference = 79.8 minutes (95% CI, 
24.3 to 135.4)].45 These results confirm that OPC 50 mg 
may be a viable option as a first-line adjunctive therapy in 
PD patients with motor fluctuations treated with L-Dopa in 
monotherapy.45
Opicapone in Clinical Practice
OPTIPARK Clinical Trial
OPTIPARK was a Phase IV, prospective, open-label, sin-
gle-arm trial conducted in Germany and the UK under 
clinical practice conditions.46 It included a broad and 
heterogeneous population of fluctuating PD patients, mir-
roring a clinical setting.
Four hundred and ninety-five PD patients with motor 
fluctuations were treated with OPC 50 mg for 3 
(Germany) or 6 (UK) months in addition to their current 
L-Dopa and other antiparkinsonian treatments.46 After 3 
months of treatment with OPC 50 mg, 71.3% showed 
clinical improvement as judged by the investigators 
(CGI-C), and for the 95 UK patients who were assessed 
at 6 months, 85.3% were also judged as improved since 
commencing treatment.46 Similarly, 76.9% of patients 
self-rated (PGI-C) improvement after 3 months, as well 
as 79.8% of patients from the UK subgroup after 6 
months of treatment with OPC.46 UPDRS motor and 
activities of daily living (ADL) scores had a clinically 
significant improvement which may indicate that treat-
ment with OPC not only increases ON time, but also 
improve the quality of ON time.46 Treatment with OPC 
was also associated with a small but significant improve-
ment in overall quality-of-life, as assessed by PDQ-8, 
and nonmotor symptoms.46 Importantly, a subgroup 
analysis for CGI-C at Month 3 confirmed improvements 
regardless of age or concomitant use of dopamine ago-
nists with or without MAO-B inhibitors at baseline.46
OPC 50 mg was generally well-tolerated, with most 
events reported as mild or moderate in severity. While the 
most common reason for withdrawal from the study was AEs 
(17.0%), nausea was the most frequent, affecting only 2% of 
patients.46 About 45.1% treatment-emergent adverse events 
(TEAEs) were considered to be at least possibly related to 
OPC; dyskinesia (11.5%) and dry mouth (6.5%) were the 
most frequently reported.46 Although dyskinesia was 
reported as a TEAE in 11.5% of patients, only five patients 
(1%) discontinued from the study due to dyskinesia, most 
patients remained on the same total daily L-Dopa dose.46
In general, the results of this large open-label study in 
PD patients with motor fluctuations are the first to confirm 
the effectiveness, safety and tolerability of once-daily OPC 
50 mg as used in routine clinical practice.
Opicapone in the Elderly
Data available on the use of OPC in the elderly is scarce. 
As mentioned above, there is a subgroup analysis of 
pooled safety data in older PD patients (>70 years old) 
from both BIPARK extension studies. This group of 
patients had more frequent TEAEs and a greater disconti-
nuation rate due to TEAEs.28
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Management of PD in geriatric patients is a great con-
cern, due to numerous comorbidities and polypharmacy that 
may increase undesirable pharmacological interactions and 
adverse effects, hampering optimal treatment.47 To investi-
gate if OPC is safe and effective in PD patients of 75 years 
old or more, in a real-world setting (OPC plus standard of 
care), a multinational, multicenter, prospective non- 
interventional study is being conducted (ClinicalTrials.gov 
Identifier: NCT03959540). Conclusions about its use in clin-
ical practice in this population may be drawn afterwards.
Pharmacovigilance Data
Safety and tolerability data from BIPARK-I and BIPARK- 
II and its 1-year open label extension studies were men-
tioned above, and published on April 28, 2016 in the 
Public Assessment Report (PAR) by EMA (EMA/ 
343011/2016).36
Treatment-emergent adverse events (TEAEs) were 
detailed in the open-label clinical setting OPTIPARK 
study, replicating some of the data from clinical trials. 
Overall, 371 (74.9%) patients experienced TEAEs, 
which were mostly assessed as mild or moderate, and 
as expected for a dopaminergic therapy in patients with 
PD. Two hundred and twenty-three (45.1%) were con-
sidered at least possibly related to treatment, the most 
frequent ones (>5%) being dyskinesia (11.5%), dry 
mouth (6.5%), and dizziness (4.8%).46 Other TEAEs 
possibly treatment-related were nausea (4.4%), constipa-
tion (4.0%), insomnia (2.4%), hallucination (2.2%), fall 
(2.0%), and diarrhea (0.6%).46 The frequency of serious 
treatment-related TEAEs was low; seven patients (1.4%) 
had more than one of the following events: anxiety, 
visual hallucination, psychotic disorder, dizziness, hyper-
tension, hypotension, tachycardia and femoral neck 
fracture.46 When analyzed by age, 56.6% from the 
older group (age above 67.7 years old) experienced any 
TEAEs, having also the highest proportion of those who 
discontinued treatment due to a TEAE.
A post-hoc analysis from OPTIPARK demonstrated 
that the majority of at least possibly drug-related TEAEs 
were reported during the first week of OPC treatment, and 
from the third week onwards the incidence of these 
TEAEs was consistently low (<4%).48 Within the first 
week, dyskinesia was the most frequently reported 
(6.5%) but with very low impact on patient discontinua-
tion (<0.5%).48
Post-marketing data on safety and tolerability is 
reported in the European public assessment report 
(EPAR) for Ongentys®, last updated on May 20, 2020.49 
Dyskinesia is consistently the most frequent TEAE 
(17.7%).49 Moreover, “common” TEAE (with no specified 
frequency) are other nervous system disorders (dizziness, 
headache, somnolence), psychiatric disorders (abnormal 
dreams, visual hallucination, insomnia), orthostatic hypo-
tension, gastrointestinal disorders (constipation, dry 
mouth, vomiting), muscle spasms, and increased blood 
creatine phosphokinase.49
Lastly, unpublished raw data of cumulative serious and 
nonserious adverse reactions of OPC are registered in 
EudraVigilance, the European database of suspected 
adverse drug reaction reports. As of November 7, 2020, 
the number of individual cases was 535. The most frequent 
cumulative events were the central nervous system disor-
ders (n=211) followed by psychiatric disorders (n=170), 
gastrointestinal complaints (n=122), and general disorders 
and administration site conditions (n=119).50
Opicapone and International 
Recommendations
Since OPC is a fairly recent drug, its inclusion in interna-
tional recommendations is still emerging.
The last European Academy of Neurology recom-
mendations on the therapeutic management of PD were 
published in 2013 (at that time, an EFNS/MDS-ES 
review);51 therefore, OPC was not yet included in this 
update, since OPC was first commercialized in Europe 
in June 2016 by BIAL.15,21,27,52 UK’s National Institute 
for Health and Care Excellence (NICE) has an evidence 
summary for OPC available online,53 published in 2017, 
but this drug has not been specifically addressed in 
NICE guidelines “Parkinson's disease in adults: diagno-
sis and management“, which have been published in 
2017 and updated in September 2020.54 COMT-i are 
mentioned, in particular ENT and TLC, with no infor-
mation concerning OPC.54
The AAN April 2006 guideline, “Practice Parameter: 
Treatment of Parkinson disease with motor fluctuations 
and dyskinesia (an evidence-based review)”, was retired 
in February 2018, since it had not been updated or reaf-
firmed in 5 years or less after the previous publication or 
reaffirmation. Nevertheless, OPC was only FDA approved 
in April 2020.37
OPC was included in the most recent MDS update on 
treatments for the motor symptoms of PD.55 OPC was 
deemed efficacious and clinically useful for treating 
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motor fluctuations in clinical practice, based on its evalua-
tion in two high-quality positive efficacy studies (BIPARK 
I and II)25,26 and one high-quality pharmacokinetic study 
which included motor outcomes.23 There were no safety 
concerns, reckoning an acceptable risk and no need of 
specialized monitoring.55 To date, OPC has not yet been 
assessed in nonfluctuating PD patients.
Management Proposal for Motor 
Fluctuations
Opicapone’s Place in Therapy
Motor complications seem to affect about 40% of patients 
after 4–6 years of L-Dopa treatment.3 Occurrence of motor 
complications appears to be related to longer disease 
Figure 1 Management proposal for motor fluctuations, considering factors that influence add-on treatment choice. 
Abbreviations: DA, dopamine agonists; COMTi, catechol-O-methyltransferase inhibitor; MAOB-I, monoamine oxidase B inhibitor; OPC, opicapone; TLC, tolcapone; ENT, 
entacapone; ICD, impulse control disorder; RLS, restless leg syndrome; OH, orthostatic hypotension; LCIG, levodopa/carbidopa intestinal gel; DBS, deep brain stimulation.
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duration4 and to higher daily doses of L-Dopa treatment.4,5 
Dyskinesia and motor fluctuations, two manifestations of 
motor complications associated to L-Dopa treatment, have 
a substantial impact on the quality-of-life of PD patients,6 
being imperative to address them appropriately.
Motor fluctuations are characterized by periods of 
reduced benefit from the medication (“off” time), which 
may be simple predictable wearing-off and/or early- 
morning off periods, or more complex unpredictable on– 
off, dose-failure, “delayed-on”, beginning-of-dose worsen-
ing or end-of-dose rebound.56 Wearing-off and early- 
morning off periods are the most common motor 
fluctuations,57,58 characterized by the re-emergence of par-
kinsonian symptoms toward the end of the treatment inter-
val between individual doses of L-Dopa and in the 
morning before the first L-Dopa dose, respectively.56 
Wearing-off worsens with disease progression and will 
eventually affect up to 80% of patients with more than 
10 years of disease duration.57 Strategies for reducing the 
time that medication is not optimally effective include 
L-Dopa dose and frequency adjustment, adding COMTi 
or MAO-Bi or adding another dopaminergic medication, 
in order to increase dopamine availability.51,59
On the basis of international recommendations and 
guidelines51,54,55 on the management of motor fluctuations, 
and evidence from OPC clinical trials and post-hoc analysis, 
we propose the flowchart in Figure 1 to approach motor 
fluctuations in clinical practice, including the role of OPC.
Conclusion
OPC is a purely peripheral COMT inhibitor with an unpre-
cedented duration of action, with favorable pharmacody-
namics with L-Dopa,8 resulting in stable and sustained 
plasma L-Dopa levels over prolonged periods, allowing 
a single daily dose regimen.
In clinical trials, OPC proved its efficacy in signifi-
cantly reducing OFF time, by approximately 1 hour, with-
out increasing troublesome dyskinesias during ON time, 
with sustained effects over 1 year. OPC is well-tolerated 
and adverse effects are those expected from dopaminergic 
stimulation.
Data from a “real world” clinical trial (OPTIPARK) 
confirmed its efficacy, safety and tolerability, making OPC 
a fairly robust therapy for the treatment of end-of-dose 
motor fluctuations in patients with PD. To date, pharma-
covigilance data did not raise any unexpected safety 
concerns.
Abbreviations
3-OMD, 3-O-methyldopa; ADL, activities of daily 
living; AE, adverse event; AUC, area under the curve; 
CGI-C, clinician global impression of change; 
COMT, catechol-O-methyltransferase; COMT-I, catechol- 
O-methyltransferase inhibitor; DA, dopamine agonists; 
ECG, electrocardiogram; EMA, European Medicines 
Agency; ENT, entacapone; EoD, end of dose; HY stage, 
Hoehn and Yahr stage; L-Dopa, levodopa; Levodopa/ 
DDCi, levodopa/DOPA decarboxylase inhibitors; MAO- 
Bi, monoamino oxidase B inhibitor; MDS, Movement 
Disorder Society; NICE, National Institute for Health and 
Care Excellence; OL, open-label; OPC, opicapone; PGI-C, 
Patients’ Global Impression of Change; PLC, placebo; 
TEAE, treatment-emergent adverse event; TLC, tolcapone.
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